---
title: "PERRIGO Co plc 2026: Revenue $1.02B, EPS $0.53— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294998560.md"
description: "Perrigo Co plc reported Q2 2026 results with net sales of $1.02B, a 3.2% YoY decline, and diluted EPS of $0.53, marking a swing to positive net income of $74.5M from a loss in the prior year. Revenue was impacted by soft consumption and lower inventory, though store-brand strength and brand momentum for Opill® and Compeed® provided support. The company completed workforce reductions and operational enhancements while reviewing its infant formula business."
datetime: "2026-08-05T17:51:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294998560.md)
  - [en](https://longbridge.com/en/news/294998560.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294998560.md)
generator: "portal-rs"
---

# PERRIGO Co plc 2026: Revenue $1.02B, EPS $0.53— 10-Q Summary

PERRIGO Co plc reported results for the 2026 quarter with net sales of $1.02B and diluted earnings per share of $0.53, marking a revenue decline versus the prior year and a swing to positive net income of $74.5M — 10-Q Summary.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$1.02B

$1.06B

(3.2%)

Net income²

$74.5M

($8.4M)

986.9%

Diluted EPS³

$0.53

($0.06)

983.3%

*¹ Reported as “Net sales”. ² Reported as “Net income (loss)”. ³ Reported as “Diluted earnings (loss) per share”.*

**Business Highlights**

-   Revenue trend: Net sales declined roughly 3–5% year-to-date, driven by soft consumption and lower retailer inventory levels, primarily in Self Care.
-   Channel & mix: Continued store-brand strength offset by lower seasonal cough/cold demand and the Dermacosmetics divestiture, which reduced sales mix.
-   Brand momentum: Opill®, ellaOne® and Compeed® gained share; Infant Formula experienced contract shipment growth despite prior production challenges.
-   Operations: Completed Supply Chain Reinvention and Project Energize targets and launched an Operational Enhancement program to reduce costs and cut roughly 7% of the workforce.
-   Quality & regulatory: Completed infant formula plant resets, strengthened quality assurance protocols after FDA interactions, and initiated a strategic review of the infant formula business.

Original SEC Filing: PERRIGO Co plc \[ PRGO \] - 10-Q - Aug. 05, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PRGO.US](https://longbridge.com/en/quote/PRGO.US.md)

## Related News & Research

- [Perrigo’s Q2 Return To Profit Amid Lower Sales Might Change The Case For Investing In PRGO](https://longbridge.com/en/news/296008507.md)
- ['Crazy overvalued': Scott Galloway says SpaceX is a '$10 to $30 stock'](https://longbridge.com/en/news/296229565.md)
- [Bio-Techne declares Q3 2026 distribution of R$ 0.01 per unit, payable Sept. 10](https://longbridge.com/en/news/296357843.md)
- [Cummins announces Q3 2026 dividend of R$ 0.14 per unit, payable Sept. 10](https://longbridge.com/en/news/296400000.md)
- [07:10 ETPort of Subs® Launches New Chicken Cordon Bleu, Seasonal Menu and Back-to-School Rewards](https://longbridge.com/en/news/296096041.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**